Xenon Pharmaceuticals Inc.
XENE· Nasdaq
XENEXenon Pharmaceuticals Inc.
Filed Mar 9, 2020 · 10-K · 69 days after period end · 0001564590-20-009385
derived · Computed from the longer spans the company filed.
| Metric | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017 | Q4 2016 |
|---|---|---|---|---|
| Revenue | — | — | $16.00K | $376.00K |
| Net Income | -$11.38M | -$8.56M | -$8.07M | -$6.00M |
| EPS Diluted | — | — | -$0.45 | -$0.34 |
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2019 · filed Mar 9, 2020 · 69 d after period end
